DOCSLIB.ORG

Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings Last Update: July 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings Last Update: July 2019 Accessable version: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings Last update: July 2019 Jane D. Siegel, MD; Emily Rhinehart, RN MPH CIC; Marguerite Jackson, PhD; Linda Chiarello, RN MS; the Healthcare Infection Control Practices Advisory Committee Acknowledgement: The authors and HICPAC gratefully acknowledge Dr. Larry Strausbaugh for his many contributions and valued guidance in the preparation of this guideline. Suggested citation: Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html Page 1 of 206 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) Healthcare Infection Control Practices Advisory Committee (HICPAC): Chair PERROTTA, Dennis M. PhD., CIC Patrick J. Brennan, MD Adjunct Associate Professor of Epidemiology Professor of Medicine University of Texas School of Public Health Division of Infectious Diseases Texas A&M University School of Rural Public University of Pennsylvania Medical School Health Executive Secretary PITT, Harriett M., MS, CIC, RN Michael Bell, MD Director, Epidemiology Division of Healthcare Quality Promotion Long Beach Memorial Medical Center National Center for Infectious Diseases Centers for Disease Control and Prevention RAMSEY, Keith M., MD Professor of Medicine Members Medical Director of Infection Control BRINSKO, Vicki L., RN, BA The Brody School of Medicine at East Carolina Infection Control Coordinator University Vanderbilt University Medical Center SINGH, Nalini, MD, MPH DELLINGER, E. Patchen., MD Professor of Pediatrics Professor of Surgery Epidemiology and International Health University of Washington School of The George Washington University Children’s Medicine National Medical Center ENGEL, Jeffrey, MD STEVENSON, Kurt Brown, MD, MPH Head General Communicable Disease Control Division of Infectious Diseases Branch Department of Internal Medicine North Carolina State Epidemiologist The Ohio State University Medical Center GORDON, Steven M., MD SMITH, Philip W., MD Chairman, Department of Infections Diseases Chief, Section of Infectious Diseases Hospital Epidemiologist Department of Internal Medicine Cleveland Clinic Foundation University of Nebraska Medical Center Department of Infectious Disease HARRELL, Lizzie J., PhD, D(ABMM) Research Professor of Molecular Genetics, HICPAC membership (past) Microbiology and Pathology Robert A. Weinstein, MD (Chair) Associate Director, Clinical Microbiology Cook County Hospital Duke University Medical Center Chicago, IL O’BOYLE, Carol, PhD, RN Jane D. Siegel, MD (Co-Chair) Assistant Professor, School of Nursing University of Texas Southwestern Medical Center University of Minnesota Dallas, TX PEGUES, David Alexander, MD Michele L. Pearson, MD (Executive Secretary) Division of Infectious Diseases Centers for Disease Control and Prevention David Geffen School of Medicine at UCLA Atlanta, GA Last update: July 2019 Page 2 of 206 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) Raymond Y.W. Chinn, MD Lorine J. Jay MPH, RN, CPHQ Sharp Memorial Hospital Liaison to Healthcare Resources Services San Diego, CA Administration Alfred DeMaria, Jr, MD Stephen F. Jencks, MD, MPH Massachusetts Department of Public Health Liaison to Center for Medicare and Medicaid Jamaica Plain, MA Services James T. Lee, MD, PhD Sheila A. Murphey, MD University of Minnesota Liaison to Food and Drug Administration Minneapolis, MN Mark Russi, MD, MPH William A. Rutala, PhD, MPH Liaison to American College of Occupational and University of North Carolina Health Care System Environmental Medicine Chapel Hill, NC Rachel L. Stricof, MPH William E. Scheckler, MD Liaison to Advisory Committee on Elimination of University of Wisconsin Tuberculosis Madison, WI Michael L. Tapper, MD Beth H. Stover, RN Liaison to Society for Healthcare Epidemiology of Kosair Children’s Hospital America Louisville, KY Robert A. Wise, MD Marjorie A. Underwood, RN, BSN CIC Liaison to Joint Commission on the Accreditation Mt. Diablo Medical Center of Healthcare Organizations Concord, CA Authors’ Associations HICPAC Liaisons Jane D. Siegel, MD William B. Baine, MD Professor of Pediatrics Liaison to Agency for Healthcare Quality Department of Pediatrics Research University of Texas Southwestern Medical Center Joan Blanchard, RN, MSN, CNOR Liaison to Association of periOperative Emily Rhinehart RN MPH CIC CPHQ Registered Nurses Vice President AIG Consultants, Inc. Patrick J. Brennan, MD Liaison to Board of Scientific Counselors Marguerite Jackson, RN PhD CIC Director, Administrative Unit, National Nancy Bjerke, RN, MPH, CIC Tuberculosis Curriculum Consortium, Liaison to Association of Professionals in Department of Medicine Infection Prevention and Control University of California San Diego Jeffrey P. Engel, MD Linda Chiarello, RN MS Liaison to Advisory Committee on Elimination of Division of Healthcare Quality Promotion Tuberculosis National Center for Infectious Diseases, CDC David Henderson, MD Liaison to National Institutes of Health Last update: July 2019 Page 3 of 206 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) TABLE OF CONTENTS Updates ................................................................................................................................................................ 7 Executive Summary .............................................................................................................................................. 8 Parts I - III: Review of the Scientific Data Regarding Transmission of Infectious Agents in Healthcare Settings .......................................................................................................................................... 9 Tables, Appendices, and Other Information ................................................................................................... 10 Appendix A: Type and Duration of Precautions Recommended for Selected Infections and Conditions . 10 Pre- Publication of the Guideline on Preventing Transmission of MDROs ..................................................... 11 Summary ........................................................................................................................................................ 11 Part I: Review of Scientific Data Regarding Transmission of Infectious Agents in Healthcare Settings.......... 13 I.A. Evolution of the 2007 Document .............................................................................................................. 13 Changes or clarifications in terminology. .................................................................................................. 14 Scope. ........................................................................................................................................................ 14 I.B. Rationale for Standard and Transmission-Based Precautions in healthcare settings .............................. 15 I.B.1. Sources of infectious agents. ............................................................................................................ 15 I.B.2. Susceptible hosts. ............................................................................................................................. 15 I.B.3. Modes of transmission. .................................................................................................................... 16 I.B.3.a. Contact transmission. ................................................................................................................ 16 I.B.3.a.i. Direct contact transmission. ............................................................................................... 16 I.B.3.a.ii. Indirect contact transmission. ........................................................................................... 17 I.B.3.b. Droplet transmission. ................................................................................................................ 18 I.B.3.c. Airborne transmission. .............................................................................................................. 19 I.B.3.d. Emerging issues concerning airborne transmission of infectious agents. ................................ 20 I.B.3.d.i. Transmission from patients. ............................................................................................... 20 I.B.3.d.ii. Transmission from the environment. ................................................................................ 21 I.B.3.e. Other sources of infection. ....................................................................................................... 21 I.C. Infectious Agents of Special Infection Control Interest for Healthcare Settings ....................................... 21 I.C.1. Epidemiologically important organisms. .......................................................................................... 22 I.C.1.a. C. difficile. .................................................................................................................................. 22 I.C.1. b. Multidrug-resistant organisms (MDROs). ...............................................................................
Load more

Recommended publications
  • Definition of a Person Under Investigation (PUI)
    Definition of a Person Under Investigation (PUI) Epidemiologic Risk (Exposure) & Clinical Features Close contact^ with a person that has laboratory-confirmed Asymptomatic§ COVID-19 OR Developed one or more of the following symptoms within 14 days of last exposure: • fever* • chills • rigors • myalgia Travel to locations on the KDHE Travel Related Quarantine Table • malaise https://www.coronavirus.kdheks.gov/175/Travel-Exposure-Related- and • headache Isolation-Quaran • sore throat • lower respiratory illness (cough, shortness of breath, or difficulty breathing) • new olfactory and taste disorders • congestion or runny nose • nausea or vomiting • diarrhea without an alternate more likely diagnosis. One or more of the following symptoms: • fever* and • chills • rigors No source of exposure has been identified • myalgia • malaise • headache • sore throat • lower respiratory illness (cough, shortness of breath, or difficulty breathing) 1 | Page • new olfactory and taste disorders • congestion or runny nose • nausea or vomiting • diarrhea without an alternate more likely diagnosis. ^ You are a "close contact" if any of the following situations happened while you spent time with a person with COVID-19, even if they didn't have symptoms: • Were within 6 feet of the person for 10 consecutive minutes or more • Had contact with the person's respiratory secretions (for example, coughed or sneezed on; kissed; contact with a dirty tissue; shared a drinking glass, food, towels, or other personal items) • Live with the person or stayed overnight for at least one night in a house with the person. The chance of spreading the virus is greater the longer an infected person or persons are close to someone.
    [Show full text]
  • Serious Fungal Infections in Peru
    Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-017-2924-9 ORIGINAL ARTICLE Serious fungal infections in Peru B. Bustamante1 & D. W. Denning2 & P. E. Campos3 Received: 21 December 2016 /Accepted: 21 December 2016 # Springer-Verlag Berlin Heidelberg 2017 Abstract Epidemiological data about mycotic diseases are This first attempt to assess the fungal burden in Peru needs limited in Peru and estimation of the fungal burden has not to be refined. We believe the figure obtained is an underesti- been previously attempted. Data were obtained from the mation, because of under diagnosis, non-mandatory reporting Peruvian National Institute of Statistics and Informatics, and lack of a surveillance system and of good data about the UNAIDS and from the Ministry of Health’s publications. size of populations at risk. We also searched the bibliography for Peruvian data on my- cotic diseases, asthma, COPD, cancer and transplants. Incidence or prevalence for each fungal disease were estimat- Introduction ed in specific populations at risk. The Peruvian population for 2015 was 31,151,543. In 2014, the estimated number of HIV/ While candidemia and invasive aspergillosis (IA) are clearly AIDS and pulmonary tuberculosis cases was 88,625, 38,581 recognized as important causes of morbidity and mortality, of them not on ART, and 22,027, respectively. A total of other mycotic agents or different clinical presentations are im- 581,174 cases of fungal diseases were estimated, representing portant in specific regions. Socio-economic and geo- approximately 1.9% of the Peruvian population. This figure ecological characteristics and size of susceptible populations includes 498,606, 17,361 and 4,431 vulvovaginal, oral and are the main determinants of variations on incidence of fungal esophageal candidiasis, respectively, 1,557 candidemia cases, infections across the world.
    [Show full text]
  • Hospice and COVID-19
    Hospice and COVID-19 For a profession whose mission is to help terminally ill patients plan their final days and guide them and their loved ones through the passage emotionally and spiritually, a global pandemic presented the ultimate challenge. ASPR TRACIE met with Sarah McSpadden, RN, MSN, MHA, President and Chief Executive Officer of The Elizabeth Hospice, to learn more about her experiences during the COVID-19 pandemic. HIGHLIGHT ASPR TRACIE Sarah, can you please tell us more about your work and the clients Related Resources you serve? COVID-19 Home-based Healthcare Sarah McSpadden (SM) and Hospice Resource Collection Our mission is to enhance the lives of those nearing the end of Engagement of Home Health life’s journey and to care for those who grieve. As a community- and Hospice Agencies in Medical based organization, we ensure that hospice care, palliative care, Surge Activities and bereavement support are available for all who face advanced Homecare and Hospice Topic serious illness. Our Elizabeth Supportive Medical Specialists provide Collection personalized medical care for adults and children who need palliative support. The Elizabeth Hospice is one of the few organizations across Medical Surge and the Role of the nation with a dedicated team specializing in perinatal and pediatric Home Health and Hospice Agencies hospice. Our comprehensive grief support program serves families from (Full Report) the community no matter how their person died or whether their person Hospice and Emergency was on service with us. Preparedness: Experiences from We were founded in 1978 when hospice was an all-volunteer program. the Field In 1982, there was a significant shift: hospice became Medicare- reimbursable and we could hire permanent staff.
    [Show full text]
  • The BET HIP-HOP AWARDS '09 Nominees Are in
    The BET HIP-HOP AWARDS '09 Nominees Are In ... Kanye West Leads The Pack With Nine Nominations As Hip-Hop's Crowning Night Returns to Atlanta on Saturday, October 10 and Premieres on BET Tuesday, October 27 at 8:00 p.m.* NEW YORK, Sept.16 -- The BET HIP-HOP AWARDS '09 nominations were announced earlier this evening on 106 & PARK, along with the highly respected renowned rapper, actor, screenwriter, film producer and director Ice Cube who will receive this year's "I AM HIP-HOP" Icon Award. Hosted by actor and comedian Mike Epps, the hip-hop event of the year returns to Atlanta's Boisfeuillet Jones Civic Center on Saturday, October 10 to celebrate the biggest names in the game - both on the mic and in the community. The BET HIP-HOP AWARDS '09 will premiere Tuesday, October 27 at 8:00 PM*. (Logo: http://www.newscom.com/cgi-bin/prnh/20070716/BETNETWORKSLOGO ) The Hip-Hop Awards Voting Academy which is comprised of journalists, industry executives, and fans has nominated rapper, producer and style aficionado Kanye West for an impressive nine awards. Jay Z and Lil Wayne follow closely behind with seven nominations, and T.I. rounds things off with six nominations. Additionally, BET has added two new nomination categories to this year's show -- "Made-You-Look Award" (Best Hip Hop Style) which will go to the ultimate trendsetter and "Best Hip-Hop Blog Site," which will go to the online site that consistently keeps hip-hop fans in the know non-stop. ABOUT ICE CUBE Veteran rapper, Ice Cube pioneered the West Coast rap movement back in the late 80's.
    [Show full text]
  • Commentary Disease Transmission Dynamics and the Evolution
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 800–801, February 1999 Commentary Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings Simon A. Levin*† and Viggo Andreasen‡ *Department of Ecology and Evolutionary Biology, Eno Hall, Princeton University, Princeton NJ 08544; and ‡Department of Mathematics, Roskilde University, DK-4000 Roskilde, Denmark Despite the tremendous benefits of antibiotics for dealing with sally, exercising little influence on their host under normal a wide range of pathogens, there is by now little doubt that conditions. Antibiotics are typically introduced to treat the their indiscriminate use has led to the emergence of novel true pathogens, and for them the problem of resistance resistant strains and a frightening new set of threats to public introduces questions concerning the length and intensity of health. Hospitals and other community settings provide an treatment, multidrug strategies, and patient compliance. (See, especially fertile ground for the spread of those types; in for example, refs. 2–4). Commensals provide a different sort particular, the recent emergence and proliferation of bacteria of problem, however. Under normal conditions, they live in resistant to both methicillin and vancomycin has engendered such places as the skin or upper respiratory tract, causing little serious concern, threatening the effectiveness of the last or no harm. On occasion, however, they become translocated available options for treatment of potentially fatal Staphylo- to sites that are normally sterile, such as the blood or lungs, coccus strains. where they may have serious harmful effects (6). Many viru- It seems clear that a considered and comprehensive strategy lence factors, for example in Staphylococcus aureus, are carried for antibiotic use is essential, permitting the intelligent de- on plasmids, and can be exchanged among different strains.
    [Show full text]
  • Valacyclovir Reduced Genital Herpes Transmission in Couples Discordant for Herpes Simplex Virus Type 2 Infection Corey L, Wald A, Patel R, Et Al
    146 THERAPEUTICS Evid Based Med: first published as 10.1136/ebm.9.5.146 on 30 September 2004. Downloaded from Valacyclovir reduced genital herpes transmission in couples discordant for herpes simplex virus type 2 infection Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20. Clinical impact ratings GP/FP/Primary care wwwwwwq Infectious diseases wwwwwqq ............................................................................................................................... In heterosexual couples who are serologically discordant for herpes simplex virus type 2 (HSV-2) infection, does once Q daily valacyclovir reduce the sexual transmission of genital herpes? METHODS MAIN RESULTS The table shows the results. Design: randomised placebo controlled trial. CONCLUSION In heterosexual couples discordant for herpes simplex virus type 2 infection, valacyclovir reduced transmission of infection. Allocation: concealed.* Commentary Blinding: blinded {participants, healthcare providers, data revious studies have shown that antiviral drugs can reduce the collectors, data analysts, and outcome assessors}À.* frequency of recurrence and subclinical shedding of viral particles.1 Follow up period: 8 months. P This important, large, well designed trial by Corey et al is the first to show an effect on the transmission of HSV-2 infection to an uninfected partner. In this study, the reduction in transmission was limited; 62 partners had Setting: 96 sites in the US, Canada, Europe, Latin America, and to take the drug daily for 8 months to prevent 1 infection, and 57 partners Australia. had to take the drug daily to prevent overall acquisition of HSV-2 infection. 2 independent predictors were found in addition to the drugs: Participants: 1498 couples >18 years who were women as the susceptible partners (hazard ratio [HR] 3.3) and duration immunocompetent, heterosexual, monogamous, in good health, of HSV-2 infection ,2 years (HR 2.9).
    [Show full text]
  • Comparative Durability and Abrasion Resistance of Natural and Synthetic
    Comparative Durability and Abrasion Resistance of Natural and Synthetic Latex Gloves Ryan Michel2 and Katrina Cornish1,2 Department of Horticulture and Crop Science, 2Department of Food, Agricultural and Biological Engineering, Ohio Agricultural Research and Development Center, The Ohio State University, Wooster, OH 44691 Abstract Medical gloves assist with the prevention of the spread of germs and are required to be worn when working with blood, body tissues, mucous membrane, and broken skin. They should provide good protection between hands and bio hazardous fluids to prevent contamination and promote safety of all healthcare workers and patients. Hence, it is critical for medical gloves to meet a standard performance criterion. Under ASTM D 3577 and D 3578, medical gloves have requirements they must meet in order to be sold and distributed as new gloves. However, there are no industry standards for gloves to meet while in use. The goal of this project was to develop a standard test for glove durability after their initial use. For the tests, gloves were worn by a mechanized prosthetic hand that was put under different conditions which are normally experienced by professionals in the medical field. This design was developed and later confirmed by Dr. Katrina Cornish: Design: Effects of media outside the glove Phosphate buffered saline (PBS), 70% ethanol, air Gloves Tested: Chloroprene, Latex 2, Nitrile, Polyvinyl Chloride and Latex 1 To evaluate glove durability during use, the gloves were immersed in different media before being subjected to contact with an abrasive surface. From this design, ranking of commercially available gloves are developed based on the time until failure of the gloves in these tests.
    [Show full text]
  • Medical Glove Guidance Manual
    On December 19, 2016, the FDA published a final rule banning powdered gloves based on the unreasonable and substantial risk of illness or injury to individuals exposed to the powdered gloves (https://www.federalregister.gov/documents/2016/12/19/2016- 30382/banned-devices-powdered-surgeons-gloves-powdered-patient- examination-gloves-and-absorbable-powder). This guidance document has not been updated to reflect the ban. FDA is assessing how to revise this guidance to represent our current thinking on medical gloves. Guidance for Industry and FDA Staff Medical Glove Guidance Manual Document issued on January 22, 2008 This document supersedes Guidance for Medical Gloves – A Workshop Manual, September 30, 1996. For questions regarding this document contact the Infection Control Devices Branch Chief at (301) 796-5580. U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Office of Device Evaluation Division of Anesthesiology, General Hospital, Infection Control, and Dental Devices Infection Control Devices Branch Preface Public Comment You may submit electronic comments and suggestions at any time for Agency consideration to http://www.regulations.gov. Submit written comments to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register. Comments may not be acted upon by the Agency until the document is next revised or updated. Additional Copies Additional copies are available from the Internet. You may also send an e-mail request to [email protected] to receive a copy of the guidance.
    [Show full text]
  • Washington State Annual Communicable Disease Report 2008
    Washington State COMMUNICABLE DISEASE REPORT 2008 "The Department of Health works to protect and improve the health of people in Washington State." WASHINGTON STATE DEPARTMENT OF HEALTH Epidemiology, Health Statistics and Public Health Laboratories Communicable Disease Epidemiology Section 1610 NE 150th Street Shoreline, WA 98155 206-418-5500 or 1-877-539-4344 COMMUNICABLE DISEASE REPORT 2008 CONTRIBUTORS COMMUNICABLE DISEASE EPIDEMIOLOGY Rebecca Baer, MPH Katelin Bugler, MPH Mary Chadden Erin Chester, MPH Natasha Close, MPH Marisa D’Angeli, MD, MPH Chas DeBolt, RN, MPH Marcia Goldoft, MD, MPH Kathy Lofy, MD Kathryn MacDonald, PhD Nicola Marsden-Haug, MPH Judith May, RN, MPH Tracy Sandifer, MPH Phyllis Shoemaker, BA Deborah Todd, RN, MPH Sherryl Terletter Doreen Terao Wayne Turnberg, PhD, MSPH COMMUNITY AND FAMILY HEALTH Maria Courogen, MPH Kim Field, RN, MSN Salem Gugsa, MPH Tom Jaenicke, MPH, MBA, MES Shana Johnny, RN, MN Julieann Simon, MSPH i Mary Selecky Secretary of Health Maxine Hayes, MD, MPH Health Officer Dennis Dennis, PhD, RN Assistant Secretary Epidemiology, Health Statistics and Public Health Laboratories Judith May, RN, MPH Office Director for Communicable Disease Tony Marfin, MD, MPH, MA State Epidemiologist for Communicable Disease Romesh Gautom, PhD Director, Public Health Laboratories Juliet VanEenwyk, PhD, MS State Epidemiologist for Non-Infectious Disease This report represents Washington State communicable disease surveillance: the ongoing collection, analysis and dissemination of morbidity and mortality data to prevent
    [Show full text]
  • The Globalization of K-Pop: the Interplay of External and Internal Forces
    THE GLOBALIZATION OF K-POP: THE INTERPLAY OF EXTERNAL AND INTERNAL FORCES Master Thesis presented by Hiu Yan Kong Furtwangen University MBA WS14/16 Matriculation Number 249536 May, 2016 Sworn Statement I hereby solemnly declare on my oath that the work presented has been carried out by me alone without any form of illicit assistance. All sources used have been fully quoted. (Signature, Date) Abstract This thesis aims to provide a comprehensive and systematic analysis about the growing popularity of Korean pop music (K-pop) worldwide in recent years. On one hand, the international expansion of K-pop can be understood as a result of the strategic planning and business execution that are created and carried out by the entertainment agencies. On the other hand, external circumstances such as the rise of social media also create a wide array of opportunities for K-pop to broaden its global appeal. The research explores the ways how the interplay between external circumstances and organizational strategies has jointly contributed to the global circulation of K-pop. The research starts with providing a general descriptive overview of K-pop. Following that, quantitative methods are applied to measure and assess the international recognition and global spread of K-pop. Next, a systematic approach is used to identify and analyze factors and forces that have important influences and implications on K-pop’s globalization. The analysis is carried out based on three levels of business environment which are macro, operating, and internal level. PEST analysis is applied to identify critical macro-environmental factors including political, economic, socio-cultural, and technological.
    [Show full text]
  • Body Substance Isolation PERSONAL PROTECTIVE
    CACC Standard 6A Body Substance Isolation AND UNIVERSAL PRECAUTIONS TRAINING PERSONAL PROTECTIVE EQUIPMENT • Blocks entry of an organism into the body – Gloves are most common • Make sure all first aid kits contain several pairs of vinyl, laytex, or Nitrile gloves • Protective eyewear, standard surgical masks, and/or respirators may be necessary • Mouth to barrier (breathing masks) are also recommended PERSONAL PROTECTIVE EQUIPMENT (PPE) • No case of disease transmission to a rescuer as a result of performing unprotected CPR in an infected victim has been documented (only 15 cases of infection reported in last 30 years!) . However, mouth to barrier devices are still strongly recommended! 1 CACC Training Aid 39-H-7 Last Modified 10 Oct 07 CACC Standard 6A UNIVERSAL PRECAUTIONS • Individuals infected with Hepatitis B Virus (HBV) or HIV may not show symptoms and may not even know they are infectious. • All human blood and body fluids should be considered infectious, and precautions should be taken to avoid contact. UNIVERSAL PRECAUTIONS • The Body Substance Isolation (BSI) technique assumes that all body fluids are a potential risk. • Follow BSI procedures even when blood and/or body fluids are not visible UNIVERSAL PRECAUTIONS • Wear appropriate PPE, such as gloves • Use absorbent barriers to soak up blood or other infectious materials • Clean the spill area with an appropriate disinfecting solution, such as bleach • Discard contaminated materials in an appropriate waste disposal container 2 CACC Training Aid 39-H-7 Last Modified 10 Oct
    [Show full text]
  • Module 6: Principles of Asepsis
    Module 6: Medical and Surgical Asepsis Module 6: Medical and Surgical Asepsis Minimum Number of Theory Hours: 2 Suggested Theory Hours: 5 Recommended Clinical Hours: 8 Statement of Purpose: The purpose of this unit is to present information about asepsis and the control of infection. Procedures and precautions to protect patient/patients/residents, health care workers and others from infection are presented, including standard precautions, transmission- based precautions and biohazardous waste management. Terminology 1. Acquired Immunodeficiency 21. Escherichia coli (E. coli) 40. Non-intact Syndrome (AIDS) 22. Excretions 41. Nosocomial 2. Airborne precautions 23. Exposure incident 42. Occupational Safety and Health 3. Asepsis 24. Flora Administration (OSHA) 4. Athlete’s foot 25. Fungus 43. Pathogens 5. Bacteria 26. Health Care-Associated Infection 44. Personal Protective Equipment 6. Barriers (HAI) (PPE) 7. Biohazard symbol 27. Hepatitis A, B, C, D, E 45. Pneumonia 8. Bloodborne 28. Herpes zoster 46. Precautions 9. Carrier spore 29. Host 47. Protozoa 10. Centers for Disease Control (CDC) 30. Immunity 48. Reservoir 11. Chain of infection 31. Infection 49. Reverse isolation 12. Communicable 32. Infectious agent 50. Rickettsia 13. Contact precautions 33. Influenza 51. Scabies 14. Contagious microbes 34. Isolation 52. Sepsis 15. Contamination 35. Lice 53. Standard precautions 16. Disinfection 36. Material Safety Data Sheet (MSDS) 54. Sterilization 17. Disorientation 37. Methicillin-Resistant 55. Streptococcus 18. Disposable Staphylococcus
    [Show full text]